Allergan (FRA:AG4) Days Inventory : 126.74 (As of Dec. 2014)

View and export this data going back to . Start your Free Trial

What is Allergan Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Allergan's Average Total Inventories for the three months ended in Dec. 2014 was €236 Mil. Allergan's Cost of Goods Sold for the three months ended in Dec. 2014 was €170 Mil. Hence, Allergan's Days Inventory for the three months ended in Dec. 2014 was 126.74.

The historical rank and industry rank for Allergan's Days Inventory or its related term are showing as below:

FRA:AG4's Days Inventory is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 158.38
* Ranked among companies with meaningful Days Inventory only.

Allergan's Days Inventory declined from Dec. 2013 (127.60) to Dec. 2014 (126.74).

Inventory Turnover measures how fast the company turns over its inventory within a year. Allergan's Inventory Turnover for the three months ended in Dec. 2014 was 0.72.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Allergan's Inventory-to-Revenue for the three months ended in Dec. 2014 was 0.15.

Allergan Days Inventory Historical Data

The historical data trend for Allergan's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergan Days Inventory Chart

Allergan Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Days Inventory

Get a 7-Day Free Trial

107.05

116.49

126.66

130.61

119.76

Allergan Quarterly Data
	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14
Days Inventory	Get a 7-Day Free Trial															127.60	130.44	121.41	128.56	126.74

Competitive Comparison of Allergan's Days Inventory

For the Drug Manufacturers - Specialty & Generic subindustry, Allergan's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allergan's Days Inventory Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allergan's Days Inventory distribution charts can be found below:

* The bar in red indicates where Allergan's Days Inventory falls into.

Allergan Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Allergan's Days Inventory for the fiscal year that ended in Dec. 2014 is calculated as

	Days Inventory (A: Dec. 2014 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2013 )	+	Total Inventories (A: Dec. 2014 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2014 )	*	Days in Period
=	( (208.269	+	240.056)	/	2 )	/	683.187	*	365
=	224.1625					/	683.187	*	365
=	119.76

Allergan's Days Inventory for the quarter that ended in Dec. 2014 is calculated as:

	Days Inventory (Q: Dec. 2014 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Sep. 2014 )	+	Total Inventories (Q: Dec. 2014 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2014 )	*	Days in Period
=	( (231.015	+	240.056)	/	2 )	/	169.58	*	365 / 4
=	235.5355					/	169.58	*	365 / 4
=	126.74

Allergan (FRA:AG4) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Allergan's Inventory Turnover for the three months ended in Dec. 2014 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	169.58	/	235.5355
	=	0.72

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Allergan's Inventory to Revenue for the three months ended in Dec. 2014 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	235.5355	/	1549.415
	=	0.15

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Allergan Days Inventory Related Terms

Thank you for viewing the detailed overview of Allergan's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Allergan (FRA:AG4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergan Inc (FRA:AG4) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Allergan IncÂ incorporated in Delaware in 1977.Â It is a multi-specialty health care company. The Company is engaged in the developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products that enable people to live life to its full potential - to see more clearly, move more freely and express themselves more fully. It offers products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets in more than 100 countries around the world. It is also engaged in specialty pharmaceutical, biologic and medical device research and development. The Company's business segments are specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces pharmaceutical products, including: ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease;Â BotoxÂ for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and over-the-counter skin care products; and urologics products. The medical devices segment produces medical devices, including: breast implants for augmentation, revision and reconstructive surgery and tissue expanders; and facial aesthetics products. The Company sells its products directly through itsÂ own sales subsidiaries in approximately 40 countries and, supplemented by independent distributors, in over 100 countries.Â Its products are sold to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies and medical practitioners. The Company also utilize distributors for its products in smaller international markets.Â The Company's competitors include Akorn, Inc., Alcon Laboratories, Inc./Novartis AG, Abbott Laboratories, Alimera Sciences, Inc., BauschÂ & Lomb, Inc., a division of Valeant, Genentech/Hoffmann La Roche AG, MerckÂ & Co., Pfizer Inc., Regeneron Pharmaceuticals, Inc. and Santen Seiyaku. Mentor and Sientra, Inc., or Sientra, a partner of Silimed, LifeCell Corporation, CR Bard Inc. The Company's operations are subject to federal, state, local and foreign environmental laws and regulations, including the U.S. Occupational Safety and Health Act, the U.S. Toxic Substances Control Act, the U.S. Resource Conservation and Recovery Act, Superfund Amendments and Reauthorization Act, Comprehensive Environmental Response, Compensation and Liability Act and other current and potential future federal, state or local regulations.

Allergan (FRA:AG4) Headlines

No Headlines